Lipella Pharmaceuticals Inc. (LIPO) Earnings History
Annual and quarterly earnings data from 2019 to 2024
Loading earnings history...
LIPO EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
LIPO Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | -573.7% | -947.2% | -935.2% |
| 2023 | -575.9% | -1055.6% | -1027.3% |
| 2022 | -1283.4% | -1406.3% | -1410.6% |
| 2021 | -461.7% | -738.7% | -719.3% |
| 2020 | -1.5% | -5.9% | -6.4% |
Download Data
Export LIPO earnings history in CSV or JSON format
Free sign-in required to download data
Lipella Pharmaceuticals Inc. (LIPO) Earnings Overview
As of May 8, 2026, Lipella Pharmaceuticals Inc. (LIPO) reported trailing twelve-month net income of -$1.26B, reflecting +22.2% year-over-year growth. The company earned $-276.57 per diluted share over the past four quarters, with a net profit margin of -935.2%.
Looking at the long-term picture, LIPO's historical earnings data spans multiple years. The company achieved its highest annual net income of -$61,656 in fiscal 2020.
Lipella Pharmaceuticals Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SIGA (-$4.04T net income, 24.6% margin), NUVL (-$450M net income), INVA ($504M net income, 63.8% margin), LIPO has room to improve margins relative to the peer group. Compare LIPO vs SIGA →
LIPO Earnings vs Peers
Earnings metrics vs comparable public companies
LIPO Historical Earnings Data (2019–2024)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$5M | -8.6% | -$5M | $-4.79 | -935.2% | -947.2% |
| 2023 | -$5M | -77.8% | -$5M | $-6.16 | -1027.3% | -1055.6% |
| 2022 | -$3M | -39.3% | -$3M | $-5.12 | -1410.6% | -1406.3% |
| 2021 | -$2M | -2925.6% | -$2M | $-4.38 | -719.3% | -738.7% |
| 2020 | $-61,656 | +0.3% | $-56,862 | $-0.23 | -6.4% | -5.9% |
| 2019 | $-61,848 | - | $-53,791 | $-0.24 | -8.9% | -7.7% |
See LIPO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LIPO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LIPO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonLIPO — Frequently Asked Questions
Quick answers to the most common questions about buying LIPO stock.
Is LIPO growing earnings?
LIPO EPS is $-276.57, with earnings growth accelerating to +22.2%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-1.3B.
What are LIPO's profit margins?
Lipella Pharmaceuticals Inc. net margin is -935.2%, with operating margin at -947.2%. Below-average margins reflect competitive or cost pressures.
How consistent are LIPO's earnings?
LIPO earnings data spans 2019-2024. The accelerating earnings trend is +22.2% YoY. Historical data enables comparison across business cycles.